Released May 3, 2017, after the close
10-Q filed May 4, 2017, 34 days after period end · 0001493152-17-004743
Q1 2017 · 10-Q
Revenue$5.23M$5.23M −4.6% vs Q1 2016−12.5% vs Q4 2016
Net Income-$90.00K-$90.00K N/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$0.04-$0.04 N/M vs Q1 2016no prior Q4 2016 on file
Operating Income-$834,000N/M
Operating Cash Flow-$466,000N/M
Free Cash Flowderived-$563,000N/M
Margins · derived
Operating margin-15.9%−0.1 pt vs Q1 2016
Net margin-1.7%+17.3 pt vs Q1 2016
What the release said
The release
Same quarter
| Metric | Q1 2017 | Q1 2016 | Q1 2015 | Q1 2014 |
|---|---|---|---|---|
| Revenue | $5.23M | $5.48M | $5.73M | $6.42M |
| Net Income | -$90.00K | -$1.04M | -$2.26M | -$649.00K |
| EPS Diluted | -$0.04 | -$0.57 | -$0.02 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR